Propafenone EG 150mg Film-Coated Tablets 몰타 - 영어 - Medicines Authority

propafenone eg 150mg film-coated tablets

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - propafenone hydrochloride - film-coated tablet - propafenone hydrochloride 150 mg - cardiac therapy

Propafenone 300mg tablets 영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

propafenone 300mg tablets

medihealth (northern) ltd - propafenone hydrochloride - oral tablet - 300mg

ARYTHMOL SR 아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

arythmol sr

abbott laboratories ireland ltd - propafenone hydrochloride - prolonged release capsules - 225 milligram

ARYTHMOL SR 아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

arythmol sr

abbott laboratories ireland ltd - propafenone hydrochloride - prolonged release capsules - 325 milligram

ARYTHMOL SR 아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

arythmol sr

abbott laboratories ireland ltd - propafenone hydrochloride - prolonged release capsules - 425 milligram

Rytmonorm 뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

rytmonorm

viatris limited - propafenone hydrochloride 150mg;  ;  ; propafenone hydrochloride 150mg - tablet - 150 mg - active: propafenone hydrochloride 150mg     excipient: croscarmellose sodium hypromellose   macrogol 400 macrogol 6000 magnesium stearate maize starch microcrystalline cellulose purified water titanium dioxide active: propafenone hydrochloride 150mg excipient: croscarmellose sodium hypromellose   macrogol 400 macrogol 6000 magnesium stearate microcrystalline cellulose pregelatinised maize starch purified water titanium dioxide - for the treatment of supraventricular extrasystoles and supraventricular tachycardias, and in wolff-parkinson-white (wpw) syndrome. also for the treatment of life-threatening documented ventricular tachyarrhythmia. the use of rytmonorm is not recommended in patients with less severe ventricular arrhythmias, even if the patients are symptomatic. because of the proarrhythimic effects of rytmonorm, its use should be reserved for patients in whom, in the opinion of the physician, the potential benefits of treatment outweigh the risks.